EA201390738A1 - Нейтрализующие антитела против ccl20 - Google Patents

Нейтрализующие антитела против ccl20

Info

Publication number
EA201390738A1
EA201390738A1 EA201390738A EA201390738A EA201390738A1 EA 201390738 A1 EA201390738 A1 EA 201390738A1 EA 201390738 A EA201390738 A EA 201390738A EA 201390738 A EA201390738 A EA 201390738A EA 201390738 A1 EA201390738 A1 EA 201390738A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
ccl20
relates
antibodies against
neutralizing antibodies
Prior art date
Application number
EA201390738A
Other languages
English (en)
Other versions
EA029419B1 (ru
Inventor
Тосио Имаи
Джеймс Брэдфорд Клайн
Тецу Кавано
Луиджи Грассо
Йосимаса Сакамото
Джаред Спайдел
Миюки Нисимура
Кендзо Мурамото
Тацуо Хоридзое
Original Assignee
ИМАИ Тосио
Джеймс Брэдфорд Клайн
КАВАНО Тецу
Луиджи Грассо
САКАМОТО Йосимаса
Джаред Спайдел
НИСИМУРА Миюки
Кендзо Мурамото
Тацуо Хоридзое
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ИМАИ Тосио, Джеймс Брэдфорд Клайн, КАВАНО Тецу, Луиджи Грассо, САКАМОТО Йосимаса, Джаред Спайдел, НИСИМУРА Миюки, Кендзо Мурамото, Тацуо Хоридзое filed Critical ИМАИ Тосио
Publication of EA201390738A1 publication Critical patent/EA201390738A1/ru
Publication of EA029419B1 publication Critical patent/EA029419B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)

Abstract

Настоящее изобретение относится к новым гуманизированным, химерным антителам и антителам мыши, специфично направленных против лиганда 20 СС-хемокина человека 20 (CCL20). Кроме того, настоящее изобретение относится к тяжелым цепям и легким цепям указанных антител. Также изобретение относится к выделенным нуклеиновым кислотам, рекомбинантным векторам и клеткам-хозяевам, которые содержат последовательность, которая кодирует тяжелую цепь и/или легкую цепь указанных антител, и к способу получения указанных антител. Антитела против CCL20 по изобретению можно использовать в терапевтических применениях для лечения, например, воспалительных и аутоиммунных нарушений и злокачественной опухоли.
EA201390738A 2010-11-19 2011-11-18 Нейтрализующие антитела против ccl20 EA029419B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41561410P 2010-11-19 2010-11-19
PCT/US2011/061525 WO2012068540A2 (en) 2010-11-19 2011-11-18 Neutralizing anti-ccl20 antibodies

Publications (2)

Publication Number Publication Date
EA201390738A1 true EA201390738A1 (ru) 2013-12-30
EA029419B1 EA029419B1 (ru) 2018-03-30

Family

ID=46084688

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390738A EA029419B1 (ru) 2010-11-19 2011-11-18 Нейтрализующие антитела против ccl20

Country Status (24)

Country Link
US (3) US8491901B2 (ru)
EP (1) EP2640744A4 (ru)
JP (3) JP5996549B2 (ru)
KR (1) KR101919170B1 (ru)
CN (1) CN103874707B (ru)
AR (1) AR084141A1 (ru)
AU (2) AU2011329647B2 (ru)
BR (1) BR112013012396A2 (ru)
CA (1) CA2818548A1 (ru)
CL (1) CL2013001403A1 (ru)
CO (1) CO6761352A2 (ru)
CR (1) CR20130228A (ru)
DO (1) DOP2013000111A (ru)
EA (1) EA029419B1 (ru)
IL (1) IL226383B (ru)
MA (1) MA34738B1 (ru)
MX (1) MX361929B (ru)
NZ (1) NZ611269A (ru)
PE (2) PE20180249A1 (ru)
SG (2) SG10201509499RA (ru)
TW (1) TWI589587B (ru)
UA (1) UA114077C2 (ru)
WO (1) WO2012068540A2 (ru)
ZA (3) ZA201303571B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101919170B1 (ko) * 2010-11-19 2018-11-15 에자이 알앤드디 매니지먼트 가부시키가이샤 중화 항-ccl20 항체
US9493566B2 (en) 2012-02-17 2016-11-15 Seattle Genetics, Inc. Antibodies to integrin AVB6 and use of same to treat cancer
WO2014062659A2 (en) * 2012-10-15 2014-04-24 Oncomed Pharmaceuticals, Inc. Methods of treating ocular diseases
MA39821B1 (fr) 2014-04-08 2020-09-30 Boston Pharmaceuticals Inc Molécules de liaison spécifiques de l'il-21 et leurs utilisations
RU2016146993A (ru) 2014-05-21 2018-06-21 Пфайзер Инк. Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака
MA41480A (fr) * 2014-10-17 2017-12-19 Glenmark Pharmaceuticals Sa Anticorps qui se lient au ccr6 et leurs utilisations
AU2015366512A1 (en) * 2014-12-17 2017-07-13 Cancer Research Technology Ltd. Anti-CXCL12 antibody molecules and their uses
EP3666282A1 (en) 2015-06-03 2020-06-17 The Medical College of Wisconsin, Inc. An engineered ccl20 locked dimer polypeptide
US11571462B2 (en) 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
ES2871252T3 (es) * 2015-07-14 2021-10-28 Medimmune Llc Método para detectar células madre cancerosas
WO2017064564A2 (en) * 2015-10-16 2017-04-20 Glaxosmithkline Intellectual Property Limited Therapeutic regimens for treating psoriatic arthritis with an anti-ccl20 antibody
CN108884127A (zh) * 2016-01-21 2018-11-23 斯克利普斯研究院 合成的阿片类疫苗
AR107505A1 (es) 2016-01-22 2018-05-09 Merck Sharp & Dohme Anticuerpos anti-factor de la coagulación xi
CA3172367A1 (en) 2016-06-14 2017-12-21 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies
SG11201903800XA (en) * 2016-11-14 2019-05-30 Dinona ANTIBODY BINDING SPECIFICALLY TO CD66c AND USE THEREOF
FR3072779A1 (fr) * 2017-10-19 2019-04-26 Sinnovial Procede d'estimation de l'efficacite d'un modulateur de la costimulation des lymphocytes t contre la polyarthrite rhumatoide apres reponse inadequate a une biotherapie
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
CN111587123A (zh) * 2017-11-09 2020-08-25 品通治疗有限公司 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物
US20220144961A1 (en) * 2019-03-11 2022-05-12 Xyence Therapeutics, Inc. Cd27-binding antibodies and uses thereof
US11827709B2 (en) * 2019-12-05 2023-11-28 Seagen Inc. Anti-AVB6 antibodies and antibody-drug conjugates
CN113087795A (zh) * 2019-12-23 2021-07-09 上海普铭生物科技有限公司 针对趋化因子cx3cl1的抗体及其应用
WO2023028451A2 (en) * 2021-08-25 2023-03-02 Ibio, Inc. Anti-cd-25 antibody
CN117106084B (zh) * 2021-12-02 2024-03-22 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4897348A (en) 1983-08-25 1990-01-30 Sri International Recombinant materials and methods for producing human connective tissue-activating peptide-III and analogs thereof
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
JP3051160B2 (ja) 1988-12-08 2000-06-12 ノバルティス・アクチエンゲゼルシャフト 好中球活性化ペプチド‐２
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5212073A (en) 1989-05-12 1993-05-18 Genetics Institute, Inc. Process for producing human JE cytokine
US5179078A (en) 1989-05-12 1993-01-12 Dana Farber Cancer Institute Method of suppressing tumor formation in vivo
WO1991004274A1 (en) 1989-09-25 1991-04-04 Genetics Institute, Inc. Method for inhibiting growth of stem cells
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
NZ237202A (en) 1990-02-23 1994-01-26 Bristol Myers Squibb Co Composition containing beta-lactam antibiotic and cationic oligopeptide
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
JPH06503710A (ja) 1990-09-14 1994-04-28 カイロン　コーポレイション 酵母細胞におけるマクロファージ誘導タンパク質（ｍｉｐ）の発現
FR2669930A1 (fr) 1990-11-29 1992-06-05 Sanofi Sa Proteine presentant une activite de type cytokine, adn recombinant, vecteur d'expression et hotes permettant son obtention.
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Tech Methoden zur Herstellung humanisierter Antikörper
US5401651A (en) 1991-10-16 1995-03-28 Walz; Alfred DNA encoding ENA-78, a neutrophil activating factor
US5306709A (en) 1991-11-15 1994-04-26 The University Of Pennsylvania Suppression of megakaryocytopoiesis by macrophage inflammatory proteins
US5346686A (en) 1992-10-05 1994-09-13 Mallinckrodt Medical, Inc. Labelled interleukin-8 and medical uses thereof
US5413778A (en) 1992-10-05 1995-05-09 The Regents Of The University Of Michigan Labelled monocyte chemoattractant protein material and medical uses thereof
EP0804070B1 (en) 1993-03-09 2000-05-24 Genzyme Corporation Process of isolation of proteins from milk
US5474983A (en) 1993-03-15 1995-12-12 The Research Foundation Of State University Of New York Method of inhibiting pro-inflammatory mediator release from basophils and mast cells
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
JPH0789866A (ja) 1993-09-21 1995-04-04 Nippon Kayaku Co Ltd 感染防御剤
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
KR970700438A (ko) 1993-12-22 1997-02-12 로버트 에이치. 벤슨 마크로파지 염증성 단백질-3,-4 및 -1감마(MACROPHAGE INFLAMMATORY PROTEINS -3,-4 AND -1sg(g))
AU7394294A (en) 1994-05-16 1995-12-05 Human Genome Sciences, Inc. Macrophage migration inhibitory factor-3
WO1995031467A1 (en) 1994-05-16 1995-11-23 Human Genome Sciences, Inc. Monocyte chemotactic protein-4
US5981230A (en) 1994-08-23 1999-11-09 Human Genome Sciences, Inc. Polynucleotide encoding chemokine β-4
CA2198206A1 (en) 1994-08-23 1996-02-29 Haodong Li Human chemokine beta-9
EP0777494B1 (en) 1994-08-23 2004-03-24 Human Genome Sciences, Inc. Human chemokine polypeptides
US6174995B1 (en) 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
ES2216001T3 (es) 1994-08-23 2004-10-16 Human Genome Sciences, Inc. Polipeptidos de quimioquina humana.
ATE262345T1 (de) 1994-08-23 2004-04-15 Human Genome Sciences Inc Menschliche chemokin-polypeptide
US6458349B1 (en) 1995-06-02 2002-10-01 Human Genome Sciences, Inc. Chemokine β-4 polypeptides
WO1996009062A1 (en) 1994-09-23 1996-03-28 University Of Nebraska Board Of Regents Polypeptide agonists and antagonists of human interleukin-8
KR100507431B1 (ko) 1994-11-07 2005-12-21 휴먼 게놈 사이언시즈, 인코포레이티드 종양괴사인자-γ
US5602008A (en) 1994-11-29 1997-02-11 Incyte Pharmaceuticals, Inc. DNA encoding a liver expressed chemokine
US6046037A (en) 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
AU2363695A (en) 1995-04-27 1996-11-18 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
AU723891B2 (en) 1995-06-05 2000-09-07 Human Genome Sciences, Inc. Human chemokine beta-11 and human chemokine alpha-1
WO1996039520A1 (en) 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human chemokine beta-12
EP0832233B1 (en) 1995-06-06 2004-10-06 Human Genome Sciences, Inc. Human chemokine beta-13
DE69631253T2 (de) 1995-10-24 2004-11-18 Human Genome Sciences, Inc. Mobilisierung von haematopoietischen stammzellen durch ein chemokin
ZA968896B (en) 1995-10-24 1997-04-24 Smithkline Beecham Corp Method of mobilizing hematopoietic stem cells
WO1997031098A1 (en) 1996-02-23 1997-08-28 Human Genome Sciences, Inc. Human chemokine polypeptides
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
AU733925C (en) 1996-03-27 2002-06-13 Icos Corporation Monocyte chemotactic protein-5 materials and methods
US6290948B1 (en) 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
JP2000514295A (ja) 1996-07-05 2000-10-31 シェーリング コーポレイション 哺乳動物のケモカイン試薬
ES2308787T3 (es) 1996-08-16 2008-12-01 Schering Corporation Antigenos de superficie de celular de mamiferos; reactivos relacionados.
AU731123B2 (en) 1996-08-16 2001-03-22 Human Genome Sciences, Inc. Human endokine alpha
GB9617923D0 (en) 1996-08-28 1996-10-09 Smithkline Beecham Plc Novel receptor
WO1998011226A2 (en) 1996-09-10 1998-03-19 Schering Corporation Mammalian chemokines, related reagents
WO1998014573A1 (en) 1996-09-30 1998-04-09 The General Hospital Corporation Mcp-4 and mcp-5: novel chemokines
WO1998017800A1 (fr) 1996-10-17 1998-04-30 Shionogi & Co., Ltd. Larc, nouvelle chimiokine cc humaine
CN1539970A (zh) 1996-10-25 2004-10-27 �Ϻ���ͨ��ѧ 嗜中性白细胞因子α
CN1213401A (zh) 1996-11-15 1999-04-07 先进研究及技术学会 Exodus化学激活素物质及方法
US7101987B2 (en) * 1996-11-27 2006-09-05 Schering Corporation CCL27 polypeptides
US8003386B1 (en) 1997-01-14 2011-08-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α and 6β
US6261801B1 (en) 1997-01-14 2001-07-17 Human Genome Sceineces, Inc. Nucleic acids encoding tumor necrosis factor receptor 5
JP4450870B2 (ja) 1997-01-28 2010-04-14 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 死ドメイン含有レセプター４（ｄｒ４：死レセプター４）、ｔｎｆ−レセプタースーパーファミリーのメンバーおよびｔｒａｉｌへの結合
ATE352618T1 (de) 1997-03-17 2007-02-15 Human Genome Sciences Inc Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
US6972323B1 (en) * 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
JP2002500509A (ja) 1997-04-30 2002-01-08 エフ．ホフマン−ラ ロシュ アーゲー ラットｓｔ３８．２ケモカイン
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
WO1998054202A1 (en) 1997-05-30 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr10
JP2002503963A (ja) 1997-06-11 2002-02-05 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ヒト腫瘍壊死因子受容体ｔｒ９
BR9908823A (pt) 1998-03-18 2000-11-21 Corixa Corp Compostos e processos para terapia e diagnóstico de câncer de pulmão
AU770555B2 (en) 1998-08-17 2004-02-26 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
US6645491B1 (en) 1999-02-03 2003-11-11 Schering Corporation Method for treating inflammatory conditions using an antibody to MIP-3α
EP1149113A1 (en) * 1999-02-03 2001-10-31 Schering Corporation Use of agonists or antagonists of mip-3a in therapy
JP5198704B2 (ja) 2000-03-03 2013-05-15 メディミューン リミティド エオタキシンに対するヒト抗体及びそれらの使用
US20040197329A1 (en) 2000-10-13 2004-10-07 Yasunori Nakayama Remedies or preventives for rheumatoid arthritis
PT1642910E (pt) 2000-12-05 2012-03-22 Alexion Pharma Inc Anticorpos concebidos de modo racional
JP4233092B2 (ja) 2001-06-07 2009-03-04 ケモセントリックス， インコーポレイテッド 細胞移動アッセイ
US7468253B2 (en) 2001-06-07 2008-12-23 Chemocentryx, Inc. Method for multiple chemokine receptor screening for antagonists using RAM assay
US7442512B2 (en) 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
DE60226641D1 (de) 2001-12-03 2008-06-26 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
AU2003225237A1 (en) 2002-05-01 2003-11-17 Human Genome Sciences, Inc. Antibodies that specifically bind to chemokine beta-4
EP1592386A4 (en) * 2003-01-24 2007-06-13 Elan Pharm Inc COMPOSITION AND METHOD FOR TREATING DEMYELINIZATION DISEASES AND PARALYSIS BY ADMINISTERING REMYELING AGENTS
US7498024B2 (en) 2003-06-03 2009-03-03 Cell Genesys, Inc. Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
DK1694706T3 (da) 2003-11-01 2012-07-16 Merck Patent Gmbh Modificeret anti-CD52-antistof
NZ554725A (en) * 2004-10-25 2009-10-30 Merck & Co Inc Anti-ADDL antibodies and uses thereof
CN101163502A (zh) 2005-02-08 2008-04-16 根茨美公司 针对TGFβ的抗体
JP2009096716A (ja) * 2006-01-19 2009-05-07 Eisai R & D Management Co Ltd 抗ｃｃｌ２０抗体による自己免疫疾患の治療
US7829678B2 (en) * 2007-11-08 2010-11-09 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
AU2008337517B2 (en) * 2007-12-14 2014-06-26 Novo Nordisk A/S Antibodies against human NKG2D and uses thereof
WO2009156994A1 (en) * 2008-06-24 2009-12-30 Hadasit Medical Research Services And Development Ltd. Ccl20-specific antibodies for cancer therapy
HRP20160857T4 (hr) * 2008-10-01 2022-12-09 Amgen Research (Munich) Gmbh Bispecifična jednolančana protutijela, specifična za visokomolekulske ciljne antigene
KR101919170B1 (ko) * 2010-11-19 2018-11-15 에자이 알앤드디 매니지먼트 가부시키가이샤 중화 항-ccl20 항체
WO2013005649A1 (ja) * 2011-07-01 2013-01-10 協和発酵キリン株式会社 抗ヒトｃｃｒ６抗体
JP7089866B2 (ja) 2017-12-22 2022-06-23 セーレン株式会社 開口部を有するシート状物およびその製造方法

Also Published As

Publication number Publication date
US20120148592A1 (en) 2012-06-14
CO6761352A2 (es) 2013-09-30
IL226383B (en) 2018-07-31
MA34738B1 (fr) 2013-12-03
KR101919170B1 (ko) 2018-11-15
IL226383A0 (en) 2013-07-31
PE20180249A1 (es) 2018-02-02
CA2818548A1 (en) 2012-05-24
MX2013005532A (es) 2013-09-26
BR112013012396A2 (pt) 2020-11-10
NZ611269A (en) 2015-03-27
AU2016200359A1 (en) 2016-02-11
JP2018042578A (ja) 2018-03-22
US20140045215A1 (en) 2014-02-13
PE20140633A1 (es) 2014-05-30
JP6289520B2 (ja) 2018-03-07
US9133273B2 (en) 2015-09-15
SG191716A1 (en) 2013-08-30
US9809647B2 (en) 2017-11-07
KR20130135872A (ko) 2013-12-11
CN103874707A (zh) 2014-06-18
JP2016093195A (ja) 2016-05-26
AU2011329647B2 (en) 2015-10-22
EA029419B1 (ru) 2018-03-30
TWI589587B (zh) 2017-07-01
CN103874707B (zh) 2017-04-19
CR20130228A (es) 2013-09-18
ZA201701051B (en) 2018-05-30
US8491901B2 (en) 2013-07-23
UA114077C2 (xx) 2017-04-25
ZA201303571B (en) 2014-12-23
WO2012068540A3 (en) 2012-09-27
TW201305204A (zh) 2013-02-01
EP2640744A4 (en) 2014-05-28
DOP2013000111A (es) 2014-06-15
JP5996549B2 (ja) 2016-09-21
CL2013001403A1 (es) 2014-08-08
JP2014502154A (ja) 2014-01-30
WO2012068540A2 (en) 2012-05-24
US20160046707A1 (en) 2016-02-18
ZA201406017B (en) 2017-06-28
MX361929B (es) 2018-12-19
SG10201509499RA (en) 2015-12-30
AU2016200359B2 (en) 2018-05-24
AR084141A1 (es) 2013-04-24
AU2011329647A1 (en) 2013-05-02
EP2640744A2 (en) 2013-09-25

Similar Documents

Publication Publication Date Title
EA201390738A1 (ru) Нейтрализующие антитела против ccl20
EA202091710A1 (ru) Антитела против cd73 и способы их применения
EA201891366A1 (ru) Гуманизированные антитела против cd73
EA201790799A1 (ru) Композиции и способы для применения для усиления иммунного ответа и терапии злокачественных опухолей
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
PH12017502129A1 (en) Antibodies against ox40 and uses thereof
PH12016502267A1 (en) Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
EA201590986A1 (ru) Антитела к ceacam5 и их применения
EA201891435A1 (ru) Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47
EA201400625A1 (ru) Антитела против pd-l1 и их применение
EA201391789A1 (ru) TNF-АЛЬФА АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, ОБЛАДАЮЩИЕ ПОВЫШЕННЫМ СВЯЗЫВАНИЕМ FcRn
MX2018006072A (es) Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
EA201590085A1 (ru) Антитела анти-egfr и их применение
EA201790986A1 (ru) Антитела к cd73 и их применения
MD4716B1 (ru) Антитела анти-LAG3 и антигенсвязывающие фрагменты
EA034770B8 (ru) Человеческие антитела к pd-1
NZ706377A (en) Il-6 antagonists and uses thereof
EA201291161A2 (ru) Связывающие csf1r антитела
NZ586053A (en) Anti-vegf antibody compositions and methods
EA201791393A3 (ru) Антитела к erbb3 и их применение
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
EA201600276A1 (ru) Анти-il-17-антитела, способ их получения и способ применения
RU2017132827A (ru) Антитело к notch4 человека
WO2015058861A8 (en) Bispecific constructs and their use in the treatment of various diseases
EA201790236A1 (ru) Антитела против vasa и способы их получения и использования

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU